The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-06 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
=== United States === In the United States, biologics are licensed through the biologics license application (BLA), then submitted to and regulated by the FDA's Center for Biologics Evaluation and Research (CBER) whereas drugs are regulated by the Center for Drug Evaluation and Research. Approval may require several years of clinical trials, including trials with human volunteers. Even after the drug is released, it will still be monitored for performance and safety risks. The manufacture process must satisfy the FDA's "Good Manufacturing Practices", which are typically manufactured in a cleanroom environment with strict limits on the amount of airborne particles and other microbial contaminants that may alter the efficacy of the drug.
(2026) study the isotopic composition of tooth enamel of ungulates from the three studied sites; the two studies provide evidence interpreted as indicative of persistence of Mediterranean seasonality and woodland ecosystems in the area of central Levantine coast between 400,000 and 100,000 years ago, resulting in existence of an ecological refugium that supporting diverse ungulate assemblages and enabled distinct, seasonal hominin foraging strategies, and evidence indicative of ecological differentiation between central and southern Levant in the studied time interval. Zeigen et al. (2026) study the isotopic composition of carbonate from the tooth enamel of the Persian fallow deers from sediments of the Amud Cave (Israel) associated with Neanderthal activity, interpreted as suggestive of exploitation of different habitats by fallow deer and gazelles from the site, and suggesting that fallow deer and gazelles were targeted by Neanderthals from the Amud Cave through different procurement strategies. Orbach et al. (2026) study the mammalian remains from a Pleistocene hyena den from the Geula Cave (Israel), reporting evidence of exploitation of similar ungulate communities by hyenas and humans during the mid-Middle Paleolithic, likely made possible by high ungulate diversity at the time, reducing competitive pressure between hyenas and humans. Hartman et al.
On 31 December 2021, in a speech, al-Burhan said he was committed to "building all the institutions of transitional government and holding free, fair, and transparent elections at their scheduled time", in July 2023. Both al-Burhan and Hemedti had ties to Vladimir Putin's government in Russia. According to Business Insider, "The two generals helped Russian President Vladimir Putin exploit Sudan's gold resources to help buttress Russian finances against Western sanctions and fund his war in Ukraine." On 9 February 2023, al-Burhan met with Russian Foreign Minister Sergey Lavrov. On 2 January 2022, Abdalla Hamdok resigned from his post of prime minister and Osman Hussein was sworn in as acting prime minister. On 4 July 2022, it was reported that al-Burhan mentioned the army will withdraw from the ongoing political talks and will allow political and revolutionary groups to form a transitional civilian government. This statement followed recent pro-democracy protests where 117 people were killed. On 10 November 2023, al-Burhan condemned Israel's actions in the Gaza Strip during the Gaza war, saying that "We declare our full solidarity with the Palestinian people and their right to establish their legitimate state on the 1967 borders." On 16 January 2025, the U.S. Treasury Department imposed sanctions on al-Burhan. According to sources the reasons were: "targeting of civilians and civilian infrastructure and denial of aid access, as well as refusal to participate in peace talks".
== Background on native platelets == Native platelets play a vital role in hemostasis, the process of blood clotting and wound healing. Also known as thrombocytes, platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow. Under healthy conditions, platelets circulate in an inactive state within the bloodstream and rapidly respond to vascular injury by initiating a complex cascade of coagulation events to prevent excessive blood loss. Native platelets are 2-3 micrometers in diameter and possess a highly specialized structure that enables their function in clot formation. Their cytoplasm contains dense granules and alpha granules, which store essential molecules such as adenosine diphosphate (ADP), serotonin, fibrinogen, and growth factors. These molecules are important for platelet activation, adhesion, and recruitment of additional platelets during vascular injury. The platelet membrane contains an abundance of glycoproteins, including integrins and receptors like glycoprotein Ib-IX-V and glycoprotein IIb/IIIa, which mediate interactions with the vascular endothelium and other platelets. A cytoskeleton composed of actin and tubulin allows platelets to change shape during activation, which extends filopodia to enhance adhesion and clot stability. Platelets engage in the following three-step process to form a stable blood clot: adhesion, activation, and aggregation.
Sources: en.wikipedia.org
== General consequences == Point mutations that occur in non-coding sequences are most often without consequences, although there are exceptions. If the mutated base pair is in the promoter sequence of a gene, then the expression of the gene may change. Also, if the mutation occurs in the splicing site of an intron, then this may interfere with correct splicing of the transcribed pre-mRNA. By altering just one amino acid, the entire peptide may change, thereby changing the entire protein. The new protein is called a protein variant. If the original protein functions in cellular reproduction then this single point mutation can change the entire process of cellular reproduction for this organism. Point germline mutations can lead to beneficial as well as harmful traits or diseases. This leads to adaptations based on the environment where the organism lives. An advantageous mutation can create an advantage for that organism and lead to the trait's being passed down from generation to generation, improving and benefiting the entire population. The scientific theory of evolution is greatly dependent on point mutations in cells. The theory explains the diversity and history of living organisms on Earth. In relation to point mutations, it states that beneficial mutations allow the organism to thrive and reproduce, thereby passing its positively affected mutated genes on to the next generation. On the other hand, harmful mutations cause the organism to die or be less likely to reproduce in a phenomenon known as natural selection.
=== Posthumous assessment === International reactions to Gaddafi's death were divided. Gaddafi was mourned as a hero by many across sub-Saharan Africa but was condemned as a brutal dictator in many Western nations. After his defeat in the civil war, Gaddafi's system of governance was dismantled and replaced by the interim government of the NTC, which legalized trade unions and freedom of the press. In January 2013, the GNC officially renamed the Jamahiriyah as the "State of Libya". Gaddafi loyalists then founded a new political party, the Popular Front for the Liberation of Libya. Led by Saif al-Islam Gaddafi, the Popular Front was allowed to participate in the future general election.
== Screening == Initial screening for CIP/CIM may be performed using an objective scoring system for muscle strength. The Medical Research Council (MRC) score is one such tool, and sometimes used to help identify CIP/CIM patients in research studies. The MRC score involves assessing strength in 3 muscle groups in the right and left sides of both the upper and lower extremities. Each muscle tested is given a score of 0–5, giving a total possible score of 60. An MRC score less than 48 is suggestive of CIP/CIM. However, the tool requires that patients be awake and cooperative, which is often not the case. Also, the screening tool is non-specific, because it does not identify the cause a person's muscle weakness. Once weakness is detected, the evaluation of muscle strength should be repeated several times. If the weakness persists, then a muscle biopsy, a nerve conduction study (electrophysiological studies), or both should be performed.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.